Navigation

Renal cell carcinoma (first line metastatic) - pazopanib

Pazopanib for the first line treatment of metastatic renal cell carcinoma

Status: History
Expected date of issue: May 2011
Referral date: November 2008
Process: STA
Notes:

Cancer reform strategy Batch 1

Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Chris Griffiths
Communications manager: Alice Law
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 15 April 2010
1st appraisal committee meeting: 13 October 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • GlaxoSmithKline (pazopanib hydrochloride)

Patient/carer groups

  • James Whale Fund for Kidney Cancer
  • Kidney Cancer UK
  • Macmillan Cancer Support

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • NHS Waltham Forest
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • Novartis (aldesleukin)
  • Pfizer (sunitinib)

Relevant research groups

  • None

Evidence Review Group

  • Aberdeen HTA
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update 

22 June 2010

 

The timelines have been extended due to an agreement with the manufacturer that they may submit additional data.

 

17 November 2010

 

On 13 October 2010, the NICE Appraisal Committee met to consider this appraisal topic, including consideration of the Patient Access Scheme submitted by the manufacturer of pazopanib (GlaxoSmithKline) and approved by the Department of Health before the meeting.  The Patient Access Scheme consists of two parts.  The Appraisal Committee considered Part A at September's Appraisal Committee meeting and agreed that it was important to consider both parts fully.  In order to do that, the Committee continued consideration of this topicat its meeting on Wednesday 10 November 2010.

 

Top


 

Key documents

This page was last updated: 23 February 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.